Imlifidase

• lmlifidase treatment tor acute inflammation in AQP4-lgG associated neuromyelitis optica spectrum disorder Recruiting
  2024-517176-38-00 Phase II 1 country Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
• Efficacy and safety trial of GNT0003 following imlifidase pre-treatment in participants aged 16 years and older with severe Crigler-Najjar s… Recruiting
  2023-510405-18-00 Phase II 1 country Genethon
• Desensitisation with imlifidase prior to kidney transplant in highly sensitised children Recruiting
  2022-500230-28-00 Phase II 4 countries Hansa Biopharma AB
• Imlifidase in ANCA-associated Vasculitis Recruiting
  2024-516727-13-00 Phase II 1 country Charite Universitaetsmedizin Berlin KöR
• A long-term follow-up trial of patients previously treated with imlifidase prior to kidney transplantation and a non-comparative transplante… Ended
  2022-502727-21-00 Phase III 8 countries Hansa Biopharma AB
• A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Imlifidase Infusion … Ended
  2024-512624-11-00 Phase I (Other) 1 country Sarepta Therapeutics Inc.
• A Phase 3 open-label, controlled, randomised, multi-centre trial comparing imlifidase and standard-of-care with standard-of-care alone in th… Ended
  2022-500121-33-01 Phase III 12 countries Hansa Biopharma AB
• Study in highly sensitised kidney transplant patients with a high degree of antibodies against the donor's kidney to see the efficacy and sa… Ended
  2024-511810-18-00 Phase III 10 countries Hansa Biopharma AB
• IMLIFIDASE IN LIVING DONOR RENAL TRANSPLANTATION: HIGHLY SENSITIZED RECIPIENTS Ended
  2024-513607-14-00 Phase II 1 country Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques Augus…

Showing 1–9 of 9 trials